Latest Strategy News

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

Orthocell’s latest Remplir™ Real World Evidence study reveals an 89.7% treatment success rate across 78 nerve repair procedures, reinforcing its clinical strength and fueling US and European market growth plans.

Mammoth Minerals reported significant shallow gold intercepts at its Excelsior Springs project in Nevada, expanded its landholding with the Imperial Gold Project acquisition, and completed the Paterson divestment, positioning itself for further exploration growth.

dorsaVi is pivoting from wearable sensors to powering next-gen exoskeletons, leveraging its neuromorphic RRAM technology to tap a projected $2 billion market by 2033.

Kingston Resources has brought forward copper concentrate production at Mineral Hill by a quarter, successfully trialing underground ore processing and advancing its multi-commodity strategy.

Australian Mines Limited's latest scoping study for its Flemington Scandium Project reveals strong financial metrics and significant upside potential tied to scandium pricing, underscoring the project's strategic position in critical minerals.

Proteomics International is pivoting from research to disciplined commercial execution of its proteomics-based diagnostic tests, focusing on distributor partnerships and reimbursement pathways in Australia and the US.

Power Minerals confirms exceptionally high-grade rare earth oxide assays at its newly acquired Morro do Ferro Project in Brazil, validating historical data and setting the stage for aggressive drilling and resource definition.

Stakk Ltd has reported a striking 186% quarter-on-quarter revenue jump to A$5.52 million in Q1 2026, driven by converting contracted clients into active billing and new engagements, underpinning strong recurring revenue and cash flow.

St George Mining has expanded its Araxá rare earths-niobium resource by 75% to 70.91Mt at 4.06% TREO, positioning the project among the world’s largest carbonatite deposits. The company also acquired land for processing facilities and forged new downstream partnerships, supported by Minas Gerais state tax incentives.

LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.

Resolution Minerals has successfully produced high-grade tungsten concentrates from historical stockpiles at its Golden Gate mine, achieving a 19-fold upgrade and strong recovery rates using simple gravity separation techniques.